Group 1a | Group 2a | Group 3a | P value | ||
---|---|---|---|---|---|
No risk factors | 1 risk factor | 2 risk factors | |||
Initial DS | 42.9 ± 9.6% | 46.0 ± 11.0% | 48.8 ± 10.5% | Overall | < 0.001 |
Group 1 vs. Group 2 | 0.001 | ||||
Group 2 vs. Group 3 | 0.075 | ||||
Group 1 vs. Group 3 | < 0.001 | ||||
Final DS | 46.0 ± 9.7% | 49.5 ± 12.0% | 55.5 ± 14.6% | Overall | < 0.001 |
Group 1 vs. Group 2 | 0.001 | ||||
Group 2 vs. Group 3 | < 0.001 | ||||
Group 1 vs. Group 3 | < 0.001 | ||||
Delta DS | 3.0 ± 6.8% | 3.5 ± 6.1% | 6.8 ± 9.9% | Overall | < 0.001 |
Group 1 vs. Group 2 | 0.703 | ||||
Group 2 vs. Group 3 | 0.001 | ||||
Group 1 vs. Group 3 | < 0.001 | ||||
Velocity of DS progression | 0.150 ± 0.402%/month | 0.154 ± 0.298%/month | 0.422 ± 0.956%/month | Overall | < 0.001 |
Group 1 vs. Group 2 | 0.995 | ||||
Group 2 vs. Group 3 | < 0.001 | ||||
Group 1 vs. Group 3 | < 0.001 |